Clinical Trials on Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Total 7745 results

Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung Cancer

China
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
National Cancer Institute (NCI)

Not yet recruiting

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Metastatic Melanoma | Locally Advanced Melanoma | Metastatic Alveolar Soft Part Sarcoma | Metastatic Non Small Cell Lung Cancer | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma | Metastatic Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer | Locally... and other conditions

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Beijing Biostar Pharmaceuticals Co., Ltd.

Recruiting

Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, United States, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

The Absorption, Metabolism and Excretion of [14C]D-0316 in Human

Advanced or Metastatic Non-small Cell Lung

China
AstraZeneca

Completed

Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m (REASON)

Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer

Germany
Shanghai Henlius Biotech

Recruiting

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

Non-small Cell Lung Cancer | Locally Advanced or Metastatic Solid Tumors

Australia
Shanghai Henlius Biotech

Active, not recruiting

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Squamous-cell Non-small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
AstraZeneca
Parexel

Completed

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS)

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Spain, United States, Italy, Korea, Republic of, Malaysia
Genzyme, a Sanofi Company

Completed

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

United States, Czech Republic, Hungary
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations

China
AstraZeneca

Completed

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. (SELECT-2)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
AstraZeneca
Quintiles, Inc.

Completed

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

United States
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Novartis Pharmaceuticals

Completed

Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations (RECAP)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring METex14 Mutations

Germany
Clovis Oncology, Inc.

Terminated

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Locally Advanced or Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Poland
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
Amgen

No longer available

Expanded Access of Sotorasib

Non Small-cell Lung Cancer | Locally Advanced Unresectable NSCLC | Locally Advanced Metastatic NSCLC

United States, Taiwan, Israel, Saudi Arabia, Brazil, Argentina
Eli Lilly and Company

Withdrawn

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Metastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung Cancer

Italy, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Allist Pharmaceuticals, Inc.

Unknown

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

China
Akeso

Not yet recruiting

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Unknown

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Institut Cancerologie de l'Ouest

Recruiting

Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy (TRAILOCLORI01)

Metastatic Non Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer

France
Qianfoshan Hospital

Recruiting

Patient's Whole Process Follow-up Management(HOPE-1) (HOPE-1)

Metastatic NSCLC | Locally Advanced Non-Small Cell Lung Cancer

China
AstraZeneca

Completed

Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer (SELECT-3)

Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV

United Kingdom
iOMEDICO AG
Roche Pharma AG

Completed

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy (CHAPLIN)

Extensive-stage Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC

Germany
Tesaro, Inc.

Active, not recruiting

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Neoplasms | Solid Tumor | Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

United States
LianBio LLC

Recruiting

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Advanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung Cancer

China
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
EMD Serono
Sanofi

Completed

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Melanoma | Breast Cancer | Colorectal Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States, Italy, Spain
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Centre Leon Berard
CREATIS Laboratory

Completed

Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma (midP)

Non-small Cell Lung Cancer | Radiation Therapy | Locally Advanced Disease | Non-metastatic Disease | Non-resectable Disease

France
International Group of Endovascular Oncology
Azienda Sanitaria Ospedaliera

Unknown

Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC) (VINORELBINA)

Locally Advanced/ Metastatic NSCLC

Italy
Amgen

Not yet recruiting

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, Australia, Brazil, Czech Republic, Russian Federation, Singapore
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Parexel

Recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

China, Netherlands, Korea, Republic of, Italy, Spain, Canada, Hungary, Japan, Argentina, France, United States, Taiwan, Poland, Serbia, United Kingdom, Hong Kong, Brazil, Germany, Belgium, Romania, India, Ireland, Australia
Taiho Oncology, Inc.

Completed

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Advanced or Metastatic Non-small Cell Lung Cancer

United States, France, Poland, Spain, Italy, Japan
Hummingbird Bioscience
Merck KGaA, Darmstadt, Germany

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Australia, Singapore
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

Locally Advanced Non-small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Locally Advanced

China
National Institute of Cancerología

Unknown

Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer

Locally Advanced Non Small-Cell Lung Canger

Mexico
WindMIL Therapeutics
Bristol-Myers Squibb

Terminated

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

NSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Metastatic

United States

Clinical Trials on Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations